Form 8-K · Current Report · Filed 2024-04-16
Cidara Therapeutics Announces Restatement of Prior Financial Statements Due to Indirect Tax Accounting Error
Cidara Therapeutics, Inc. announced on April 11, 2024, that it will restate its previously issued audited consolidated financial statements for fiscal years 2021 and 2022, and unaudited condensed consolidated financial statements for each quarterly period in 2022 and 2023. The restatement is due to the company's failure to appropriately account for indirect taxes related to its supply chain activities, leading to understatements of accrued liabilities and operating expenses. The company expects to record an accrued liability for indirect taxes of approximately $7.6 million for 2021 and $11.5 million for 2022, with related increases in operating expenses and beginning accumulated deficit. The restatement will be completed in the near term as part of the Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
- Filer
- Cidara Therapeutics Inc. CDTX · NASDAQ
- Filed
- Accession
- 0001610618-24-000035
- CIK
- 0001610618
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Non-Reliance on Previously Issued Financial Statements
Market reaction
Close before filing
$16.50
Next session
-12.5%
Since filing
+1241.7%
Latest close
$221.38
What happened, not what will happen — closing prices around the filing date.
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Never miss another CDTX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.